Table 1.
Patient characteristics
| Patient | Sex | Age, y | Diagnosis | Year of diagnosis | Stage/classification | Treatment | Previous treatment | S aureus infection∗ |
|---|---|---|---|---|---|---|---|---|
| SS1 | M | 75 | SS | 2015 | IVA1 (T4, N0, M0, B2) | Doxorubicin | PUVA, ECP, IFN-α, bexarotene, mogamulizumab | Yes† |
| SS2 | M | 71 | SS | 2017 | IVA1 (T4, N1, M0, B2) | Vorinostat | ECP, UVB, IFN-α, mogamulizumab, brentuximab vedotin | Yes† |
| SS3 | M | 64 | SS | 2021 | IVA1 (T4, N1, B2, M0) | ECP, alitretinoin | UVB, acitretin, brodalumab, topical corticosteroids | Yes† |
| SS4 | M | 85 | SS | 2012 | NA | ECP, IFN-α | PUVA, IFN-α, bexarotene | Yes‡ |
| SS5 | M | NA | SS | 2013 | B2 | Blood collected before ECP treatment | NA | NA |
| SS6 | M | 67 | SS | 2016 | B2 | ECP, IFN-α, bexarotene, TSEI | Acitretin, chloroquine, doxycycline, prednisolone | Yes‡ |
| SS7 | M | 65 | SS | 2016 | B2 | ECP, IFN-α, prednisolone | Ifliximab, ustekinumab, secukinumab, adalimumab, acitretin, alitretinoin, prednisolone | Yes‡ |
| SS8 | F | 74 | SS | 2016 | B2 | ECP | Prednisolone, methotrexate, PUVA | No‡ |
| SS9 | M | 79 | SS | 2016 | B2 | ECP | Ifliximab, etanercept, adalimumab, ustekinumab, cyclosporin, PUVA | Yes‡ |
| SS10 | M | 58 | SS | 2018 | B2 | ECP, IFN-α, prednisolone | Prednisolone, methotrexate | Yes‡ |
| SS11 | M | 82 | SS | 2018 | B2 | ECP | NA | Yes‡ |
| SS12 | M | 77 | SS | 2017 | B2 | ECP, brentuximab vedotin | PUVA, UVB, methotrexate, IFN-α, bexarotene | Yes‡ |
| SS13 | M | 71 | SS/leukemic MF | 2014 | IVA2 (pT4, N3, B2, M0) | Gemcitabine | UVB, ECP, bexarotene, methotrexate | NA |
| SS14 | M | 80 | SS | 2011 | IVB (pT4p, N3, M1) | ECP, brentuximab vedotin | UVB, methotrexate, bexarotene, PUVA, gemcitabine, prednisolone, domatinostat (4SC-202), doxorubicin, brentuximab vedotin, ECP, bendamustine, dimethyl fumarate | Yes† |
| SS15 | F | 85 | SS | 2014 | IVA1 (pT4, N0, B2, M0) | Bexarotene | Methotrexate | NA |
| SS16 | F | 60 | SS | 2020 | IVA1 (T4, N1, B2, M0) | ECP, methotrexate | Methotrexate | NA |
| SS17 | M | 77 | SS | 2022 | III | Prednisolone, topical corticosteroid, grade IV | No previous treatment | Yes‡ |
| SS18 | M | 84 | SS | 2022 | IVA (T4, N0, M0, B2) | Alemtuzumab | ECP | Yes‡ |
| SS19 | F | 71 | SS | 2023 | IVA (T4, N0, M0, B2) | Acitretin, ECP | No previous treatment | Yes‡ |
| SS20 | M | 67 | SS | 2023 | IVA1 (T4, N2, B2, M0) | ECP, mogamulizumab | CHOP, brentuximab vedotin, cisplatin, cytarabine | Yes† |
Treatment indicates the patient clinical treatments at the time point of blood collection where PBMCs were isolated and used for experiments.
ECP, extracorporal photopheresis; IFN, interferon; F, female; M, male; MF, mycosis fungoides; NA, not available; PUVA, psoralen and ultraviolet A; SS, Sézary syndrome; TSEI, total skin electron irradiation; UVB, ultraviolet B.
∗
S aureus infection during or before the sample collection.
†
Data obtained from clinical swabs.
‡
Data based on the measure of immunoglobulin G levels against S aureus proteins in patient serum by enzyme-linked immunosorbent assay (supplemental Methods).